Phase 1 Clinical Trial in Patients with Advanced B-Cell Malignancies Expected to Begin in the Second Half of 2022 NEW YORK --(BUSINESS WIRE)--Jun. 28, 2022-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered,
NEW YORK --(BUSINESS WIRE)--Jun. 22, 2022-- Schrödinger, Inc . (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today will host its second annual Educator’s Day , bringing together K-12 and university educators from across the
NEW YORK --(BUSINESS WIRE)--Jun. 2, 2022-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference .
NEW YORK --(BUSINESS WIRE)--May 19, 2022-- Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022 . Mr.
NEW YORK --(BUSINESS WIRE)--May 13, 2022-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate at the Citi Biotech Virtual Co-Panel Day.
Software Revenue of $33.1 Million , a 26 Percent Increase Over First Quarter of 2021 ; Total Revenue of $48.7 Million , up 51 Percent Over First Quarter of 2021 Company Maintains Full-Year 2022 Financial Outlook Internal Pipeline Progressing, With IND Submission for SGR-1505, Schrödinger’s MALT1
NEW YORK --(BUSINESS WIRE)--Apr. 20, 2022-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, will report its first quarter 2022 financial results on Wednesday, May 4, 2022 , after the financial markets close.
NEW YORK --(BUSINESS WIRE)--Apr. 19, 2022-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today reported that on April 15, 2022 , the company granted non-statutory stock options to purchase an aggregate of
Schrödinger’s Highly Selective and Structurally-Distinct Wee1 Inhibitors Demonstrate Strong Anti-Tumor Activity in Tumor Models On Track to Select a Wee1 Development Candidate in 2022 NEW YORK --(BUSINESS WIRE)--Apr. 12, 2022-- Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based software
NEW YORK --(BUSINESS WIRE)--Mar. 17, 2022-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today reported that on March 15, 2022 , the company granted non-statutory stock options to purchase an aggregate of